Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Pathology & Oncology Research
Erschienen in: Pathology & Oncology Research 3/2017

27.10.2016 | Review

The Role of IL-37 in Non-Cancerous Diseases

verfasst von: Vivi A. Ding, Ziwen Zhu, Alyse A. Mantz, Huaping Xiao, Mark R. Wakefield, Qian Bai, Yujiang Fang

Erschienen in: Pathology & Oncology Research | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

IL-37 is a newly discovered cytokine belonging to IL-1 family consisting of 11 members, which have similar β-barrel structures and associate with Ig-like receptors. Extensive studies have been done with IL-37 since its discovery. These studies suggest that IL-37 does not only play a role in tumorigenesis, but also has anti-inflammatory properties in immune responses through the down regulation of pro-inflammatory molecules. We have previously reviewed the role of IL-37 in cancer. Here, we will focus on the role of IL-37 in non-cancerous Diseases. Such a study might be helpful to design new strategies to treat IL-37 associated diseases.
Literatur
1.
Dinarello CA (2013) Overview of the interleukin-1 family of ligands and receptors. In: Seminars in immunology, vol 6. Elsevier, pp 389–393
2.
3.
Boraschi D, Lucchesi D, Hainzl S, Leitner M, Maier E, Mangelberger D, Oostingh GJ, Pfaller T, Pixner C, Posselt G (2011) IL-37: a new anti-inflammatory cytokine of the IL-1 family. Eur Cytokine Netw 22(3):127–147PubMed
4.
Dinarello C, Arend W, Sims J, Smith D, Blumberg H, O'Neill L, Goldbach-Mansky R, Pizarro T, Hoffman H, Bufler P (2010) IL-1 family nomenclature. Nat Immunol 11(11):973–973CrossRefPubMedPubMedCentral
5.
Van de Veerdonk FL, Netea MG (2013) New insights in the immunobiology of IL-1 family members. Front Immunol 4(167):1–11
6.
Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, Dinarello CA (2010) IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol 11(11):1014–1022CrossRefPubMedPubMedCentral
7.
Busfield S, Comrack C, Yu G, Chickering T, Smutko J, Zhou H, Leiby K, Holmgren L, Gearing D, Pan Y (2000) Identification and gene organization of three novel members of the IL-1 family on human chromosome 2. Genomics 66(2):213–216CrossRefPubMed
8.
Kumar S, McDonnell PC, Lehr R, Tierney L, Tzimas MN, Griswold DE, Capper EA, Tal-Singer R, Wells GI, Doyle ML (2000) Identification and initial characterization of four novel members of the interleukin-1 family. J Biol Chem 275(14):10308–10314CrossRefPubMed
9.
Pan G, Risser P, Mao W, Baldwin DT, Zhong AW, Filvaroff E, Yansura D, Lewis L, Eigenbrot C, Henzel WJ (2001) IL-1H, an interleukin 1-related protein that binds IL-18 receptor/IL-1Rrp. Cytokine 13(1):1–7CrossRefPubMed
10.
Smith DE, Renshaw BR, Ketchem RR, Kubin M, Garka KE, Sims JE (2000) Four new members expand the interleukin-1 superfamily. J Biol Chem 275(2):1169–1175CrossRefPubMed
11.
Taylor SL, Renshaw BR, Garka KE, Smith DE, Sims JE (2002) Genomic organization of the interleukin-1 locus. Genomics 79(5):726–733CrossRefPubMed
12.
Kumar S, Hanning CR, Brigham-Burke MR, Rieman DJ, Lehr R, Khandekar S, Kirkpatrick RB, Scott GF, Lee JC, Lynch FJ (2002) Interleukin-1F7B (IL-1H4/IL-1F7) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-γ production. Cytokine 18(2):61–71CrossRefPubMed
13.
Luo Y, Cai X, Liu S, Wang S, Nold-Petry CA, Nold MF, Bufler P, Norris DA, Dinarello CA, Fujita M (2013) 171: IL-37 suppresses contact hypersensitivity by inducing tolerogenic dendritic cells. Cytokine 63(3):283CrossRef
14.
Gao W, Kumar S, Lotze MT, Hanning C, Robbins PD, Gambotto A (2003) Innate immunity mediated by the cytokine IL-1 homologue 4 (IL-1H4/IL-1F7) induces IL-12-dependent adaptive and profound antitumor immunity. J Immunol 170(1):107–113CrossRefPubMed
15.
Ding VA, Zhu Z, Xiao H, Wakefield MR, Bai Q, Fang Y (2016) The role of IL-37 in cancer. Med Oncol 33(7):1–7CrossRef
16.
Bufler P, Gamboni-Robertson F, Tania A, Soo-Hyun K, Dinarello CA (2004) Interleukin-1 homologues IL-1F7b and IL-18 contain functional mRNA instability elements within the coding region responsive to lipopolysaccharide. Biochem J 381(2):503–510CrossRefPubMedPubMedCentral
17.
Bulau A-M, Nold MF, Li S, Nold-Petry CA, Fink M, Mansell A, Schwerd T, Hong J, Rubartelli A, Dinarello CA (2014) Role of caspase-1 in nuclear translocation of IL-37, release of the cytokine, and IL-37 inhibition of innate immune responses. Proc Natl Acad Sci 111(7):2650–2655CrossRefPubMedPubMedCentral
18.
Martinon F, Tschopp J (2007) Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ 14(1):10–22CrossRefPubMed
19.
Bufler P, Azam T, Gamboni-Robertson F, Reznikov LL, Kumar S, Dinarello CA, Kim S-H (2002) A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity. Proc Natl Acad Sci 99(21):13723–13728CrossRefPubMedPubMedCentral
20.
Dinarello CA (1998) Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol 16(5–6):457–499CrossRefPubMed
21.
Novick D, Kim S-H, Fantuzzi G, Reznikov LL, Dinarello CA, Rubinstein M (1999) Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 10(1):127–136CrossRefPubMed
22.
23.
Wald D, Qin J, Zhao Z, Qian Y, Naramura M, Tian L, Towne J, Sims JE, Stark GR, Li X (2003) SIGIRR, a negative regulator of toll-like receptor–interleukin 1 receptor signaling. Nat Immunol 4(9):920–927CrossRefPubMed
24.
Xiao H, Gulen MF, Qin J, Yao J, Bulek K, Kish D, Altuntas CZ, Wald D, Ma C, Zhou H (2007) The toll–interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis. Immunity 26(4):461–475CrossRefPubMed
25.
Magne D, Palmer G, Barton JL, Mézin F, Talabot-Ayer D, Bas S, Duffy T, Noger M, Guerne P-A, Nicklin MJ (2006) The new IL-1 family member IL-1F8 stimulates production of inflammatory mediators by synovial fibroblasts and articular chondrocytes. Arthritis Res Ther 8(3):R80CrossRefPubMedPubMedCentral
26.
Nold-Petry CA, Lo CY, Rudloff I, Elgass KD, Li S, Gantier MP, Lotz-Havla AS, Gersting SW, Cho SX, Lao JC (2015) IL-37 requires the receptors IL-18R [alpha] and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction. Nat Immunol 16(4):354–365CrossRefPubMed
27.
Li S, Neff CP, Barber K, Hong J, Luo Y, Azam T, Palmer BE, Fujita M, Garlanda C, Mantovani A (2015) Extracellular forms of IL-37 inhibit innate inflammation in vitro and in vivo but require the IL-1 family decoy receptor IL-1R8. Proc Natl Acad Sci 112(8):2497–2502CrossRefPubMedPubMedCentral
28.
Sharma S, Kulk N, Nold MF, Gräf R, Kim S-H, Reinhardt D, Dinarello CA, Bufler P (2008) The IL-1 family member 7b translocates to the nucleus and down-regulates proinflammatory cytokines. J Immunol 180(8):5477–5482CrossRefPubMed
29.
Bulau A-M, Gruschka A, Schwaiger R, Dinarello CA, Bufler P (2013) 30: anti-IL-37 antibody abrogates the protection in IL-37 transgenic mice to LPS-induced septic shock. Cytokine 63(3):250CrossRef
30.
Grimsby S, Jaensson H, Dubrovska A, Lomnytska M, Hellman U, Souchelnytskyi S (2004) Proteomics-based identification of proteins interacting with Smad3: SREBP-2 forms a complex with Smad3 and inhibits its transcriptional activity. FEBS Lett 577(1):93–100CrossRefPubMed
31.
Bouma G, Strober W (2003) The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 3(7):521–533CrossRefPubMed
32.
McNamee EN, Masterson JC, Jedlicka P, McManus M, Grenz A, Collins CB, Nold MF, Nold-Petry C, Bufler P, Dinarello CA (2011) Interleukin 37 expression protects mice from colitis. Proc Natl Acad Sci 108(40):16711–16716CrossRefPubMedPubMedCentral
33.
34.
Imaeda H, Takahashi K, Fujimoto T, Kasumi E, Ban H, Bamba S, Sonoda H, Shimizu T, Fujiyama Y, Andoh A (2013) Epithelial expression of interleukin-37b in inflammatory bowel disease. Clin Exp Immunol 172(3):410–416CrossRefPubMedPubMedCentral
35.
Crispín JC, Liossis S-NC, Kis-Toth K, Lieberman LA, Kyttaris VC, Juang Y-T, Tsokos GC (2010) Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med 16(2):47–57CrossRefPubMedPubMedCentral
36.
37.
Su D-L, Lu Z-M, Shen M-N, Li X, Sun, L-Y (2012) Roles of pro-and anti-inflammatory cytokines in the pathogenesis of SLE. Biomed Res Int
38.
Bezalel S, Asher I, Elbirt D, Sthoeger ZM (2012) Novel biological treatments for systemic lupus erythematosus: current and future modalities. Isr Med Assoc J 14(8):508–514PubMed
39.
Song L, Qiu F, Fan Y, Ding F, Liu H, Shu Q, Liu W, Li X (2013) Glucocorticoid regulates interleukin-37 in systemic lupus erythematosus. J Clin Immunol 33(1):111–117CrossRefPubMed
40.
Ye L, Ji L, Wen Z, Zhou Y, Hu D, Li Y, Yu T, Chen B, Zhang J, Ding L (2014) IL-37 inhibits the production of inflammatory cytokines in peripheral blood mononuclear cells of patients with systemic lupus erythematosus: its correlation with disease activity. J Transl Med 12:69CrossRefPubMedPubMedCentral
41.
Li C, Zhao P, Sun X, Che Y, Jiang, Y (2013) Elevated levels of cerebrospinal fluid and plasma interleukin-37 in patients with Guillain-Barré syndrome. Mediat Inflamm
42.
Xia T, Zheng, X-f, Qian, B-h, Fang, H, Wang, J-j, Zhang, L-l, Pang, Y-f, Zhang, J, Wei, X-q, Xia, Z-f (2015) plasma interleukin-37 is elevated in patients with rheumatoid arthritis: its correlation with disease activity and Th1/Th2/Th17-related cytokines. Dis Markers
43.
Yang L, Zhang J, Tao J, Lu T (2015) Elevated serum levels of interleukin-37 are associated with inflammatory cytokines and disease activity in rheumatoid arthritis. APMIS 123(12):1025–1031CrossRefPubMed
44.
45.
46.
Feldmann M, Maini R (1999) The role of cytokines in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford, England) 38:3–7
47.
48.
Moschen AR, Molnar C, Enrich B, Geiger S, Ebenbichler CF, Tilg H (2011) Adipose and liver expression of interleukin (IL)-1 family members in morbid obesity and effects of weight loss. Mol Med 17(7):840PubMedPubMedCentral
49.
Ballak DB, Van Diepen JA, Moschen AR, Jansen HJ, Hijmans A, Groenhof G-J, Leenders F, Bufler P, Boekschoten MV, Müller M Kersten S, Li S, et al. (2014) IL-37 protects against obesity-induced inflammation and insulin resistance. Nature communications 5:4711
50.
Bulau A-M, Fink M, Maucksch C, Kappler R, Mayr D, Wagner K, Bufler P (2011) In vivo expression of interleukin-37 reduces local and systemic inflammation in concanavalin A-induced hepatitis. Sci World J 11:2480–2490CrossRef
51.
Sakai N, Van Sweringen HL, Belizaire RM, Quillin RC, Schuster R, Blanchard J, Burns JM, Tevar AD, Edwards MJ, Lentsch AB (2012) Interleukin-37 reduces liver inflammatory injury via effects on hepatocytes and non-parenchymal cells. J Gastroenterol Hepatol 27(10):1609–1616CrossRefPubMedPubMedCentral
52.
Colletti L, Remick D, Burtch G, Kunkel S, Strieter R, Campbell D Jr (1990) Role of tumor necrosis factor-alpha in the pathophysiologic alterations after hepatic ischemia/reperfusion injury in the rat. J Clin Investig 85(6):1936CrossRefPubMedPubMedCentral
53.
Husted T, Blanchard J, Schuster R, Shen H, Lentsch A (2006) Potential role for IL-23 in hepatic ischemia/reperfusion injury. Inflamm Res 55(5):177–178CrossRefPubMed
54.
Lentsch AB, Yoshidome H, Cheadle WG, Miller FN, Edwards MJ (1998) Chemokine involvement in hepatic ischemia/reperfusion injury in mice: roles for macrophage inflammatory protein-2 and KC. Hepatology 27(4):1172–1177CrossRefPubMed
55.
Lentsch AB, Yoshidome H, Kato A, Warner RL, Cheadle WG, Ward PA, Edwards MJ (1999) Requirement for interleukin-12 in the pathogenesis of warm hepatic ischemia/reperfusion injury in mice. Hepatology 30(6):1448–1453CrossRefPubMed
56.
Suzuki S, Toledo-Pereyra LH (1994) Interleukin 1 and tumor necrosis factor production as the initial stimulants of liver ischemia and reperfusion injury. J Surg Res 57(2):253–258CrossRefPubMed
57.
Wanner GA, Ertel W, Müller P, Höfer Y, Leiderer R, Menger MD, Messmer K (1996) Liver ischemia and reperfusion induces a systemic inflammatory response through Kupffer cell activation. Shock 5(1):34–40CrossRefPubMed
58.
Jaeschke H (2006) Mechanisms of liver injury. II Mechanisms of neutrophil-induced liver cell injury during hepatic ischemia-reperfusion and other acute inflammatory conditions. Am J Physiol Gastrointest Liver Physiol 290(6):G1083–G1088CrossRefPubMed
59.
Jaeschke H, Farhood A (1991) Neutrophil and Kupffer cell-induced oxidant stress and ischemia-reperfusion injury in rat liver. Am J Physiol Gastrointest Liver Physiol 260(3):G355–G362
60.
Li C, Ji H, Cai Y, Ayana DA, Lv P, Liu M, Jiang Y (2013) Serum interleukin-37 concentrations and HBeAg seroconversion in chronic HBV patients during telbivudine treatment. J Interf Cytokine Res 33(10):612–618CrossRef
61.
Wu B-w, Q-t Z, Meng K, Q-w J (2013) The potential role of IL-37 in atherosclerosis. Die Pharmazie-An Int J Pharm Sci 68(11):857–860
62.
Ji Q, Zeng Q, Huang Y, Shi Y, Lin Y, Lu Z, Meng K, Wu B, Yu K, Chai, M (2014) Elevated plasma IL-37, IL-18, and IL-18BP concentrations in patients with acute coronary syndrome. Mediat Inflamm
63.
Wu B, Meng K, Ji Q, Cheng M, Yu K, Zhao X, Tony H, Liu Y, Zhou Y, Chang C (2014) Interleukin-37 ameliorates myocardial ischaemia/reperfusion injury in mice. Clin Exp Immunol 176(3):438–451CrossRefPubMedPubMedCentral
64.
Højen JF, Rasmussen TA, Andersen KLD, Winckelmann AA, Laursen RR, Gunst JD, Møller HJ, Fujita M, Østergaard L, Søgaard OS (2015) Interleukin-37 expression is increased in chronic HIV-1-infected individuals and is associated with inflammation and the size of the total viral reservoir. Mol Med 21(1):337CrossRefPubMedPubMedCentral
65.
Coll-Miró M, Francos-Quijorna I, Santos-Nogueira E, Torres-Espin A, Bufler P, Dinarello CA, López-Vales R (2016) Beneficial effects of IL-37 after spinal cord injury in mice. Proceedings of the National Academy of Sciences:201523212
Metadaten
Titel
The Role of IL-37 in Non-Cancerous Diseases
verfasst von
Vivi A. Ding
Ziwen Zhu
Alyse A. Mantz
Huaping Xiao
Mark R. Wakefield
Qian Bai
Yujiang Fang
Publikationsdatum
27.10.2016
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 3/2017
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-016-0137-7

Weitere Artikel der Ausgabe 3/2017

Pathology & Oncology Research 3/2017 Zur Ausgabe

Original Article

Molecular Profiling of Thymoma and Thymic Carcinoma: Genetic Differences and Potential Novel Therapeutic Targets

Original Article

Prognostic Factors for Renal Cell Carcinoma Subtypes Diagnosed According to the 2016 WHO Renal Tumor Classification: a Study Involving 928 Patients

Original Article

The Role of CD90 in the Differential Diagnosis of Pleural Malignant Mesothelioma, Pulmonary Carcinoma and Comparison with Calretının

Original Article

Differing Lymphatic Vessels Density in Salivary Adenoid Cystic Carcinoma and Pleomorphic Adenoma

Original Article

Transformed Root Extract of Leonurus sibiricus Induces Apoptosis through Intrinsic and Extrinsic Pathways in Various Grades of Human Glioma Cells

Original Article

Significance of OCT1 Expression in Acute Myeloid Leukemia

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise